Healthcare provider profile · identity verified

Anjali Kumar, MD

Pulmonary Disease · DETROIT, MI · NPI 1902988942

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	1232	126
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	792	70
Baclofen	Baclofen	639	88
Diclofenac Sodium	Diclofenac Sodium	579	114
Albuterol Sulfate Hfa	Albuterol Sulfate	527	85
Tizanidine Hcl	Tizanidine Hcl	502	62
Lidocaine	Lidocaine	431	58
Famotidine	Famotidine	411	62
Gabapentin	Gabapentin	296	33
Naloxone Hcl	Naloxone Hcl	275	158
Esomeprazole Magnesium	Esomeprazole Magnesium	255	44
Diclofenac Sodium Er	Diclofenac Sodium	237	28
Amlodipine Besylate	Amlodipine Besylate	226	30
Atorvastatin Calcium	Atorvastatin Calcium	202	29
Omeprazole	Omeprazole	189	27
Dexlansoprazole Dr	Dexlansoprazole	166	32
Pregabalin	Pregabalin	159	18
Torsemide	Torsemide	158	22
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	126	29
Lisinopril	Lisinopril	124	19
Metoprolol Tartrate	Metoprolol Tartrate	123	17
Chlorzoxazone	Chlorzoxazone	119	38
Acetaminophen-Codeine	Acetaminophen With Codeine	109	13
Naproxen	Naproxen	106	15
Metformin Hcl	Metformin Hcl	104	16
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	96	39
Fenofibrate	Fenofibrate Nanocrystallized	93	13
Metoprolol Succinate	Metoprolol Succinate	73	suppressed
Carvedilol	Carvedilol	71	12
Naproxen Sodium	Naproxen Sodium	66	11
Hydralazine Hcl	Hydralazine Hcl	65	suppressed
Lansoprazole	Lansoprazole	65	13
Celecoxib	Celecoxib	64	suppressed
Clopidogrel	Clopidogrel Bisulfate	56	suppressed
Furosemide	Furosemide	53	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	49	suppressed
Ibuprofen	Ibuprofen	47	suppressed
Simvastatin	Simvastatin	46	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	45	11
Diclofenac Potassium	Diclofenac Potassium	45	27
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	45	suppressed
Clonidine Hcl	Clonidine Hcl	43	suppressed
Naproxen Sodium Cr	Naproxen Sodium	43	25
Ventolin Hfa	Albuterol Sulfate	38	16
Jardiance	Empagliflozin	37	suppressed
Nifedipine Er	Nifedipine	36	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	33	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	33	suppressed
Azithromycin	Azithromycin	31	23
Atenolol	Atenolol	30	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	29	suppressed
Losartan Potassium	Losartan Potassium	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Eliquis	Apixaban	27	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Naproxen Sodium Er	Naproxen Sodium	20	11
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Ozempic	Semaglutide	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Promethazine Hcl	Promethazine Hcl	17	11
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Spironolactone	Spironolactone	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Cephalexin	Cephalexin	13	suppressed
Glipizide	Glipizide	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Methimazole	Methimazole	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error